Thermo Fisher Scientific Inc. $TMO Shares Sold by C WorldWide Group Holding A S

Key Points

• C WorldWide Group Holding A S reduced its Thermo Fisher Scientific stake by 15% in the fourth quarter, selling 112,675 shares and leaving it with 638,428 shares valued at about $370 million.
• Thermo Fisher posted a strong quarter, with EPS of $5.44 and revenue of $11.01 billion, both ahead of estimates; the company also guided FY2026 EPS to $24.64-$25.12.
• Sentiment remains mixed: several analysts still rate the stock a Buy, but recent price-target cuts from firms like Stifel and Wells Fargo have pressured expectations, even as Thermo Fisher raised its quarterly dividend to $0.47 per share.

C WorldWide Group Holding A S cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 15.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 638,428 shares of the medical research company's stock after selling 112,675 shares during the quarter. Thermo Fisher Scientific makes up approximately 6.5% of C WorldWide Group Holding A S's investment portfolio, making the stock its 5th largest position. C WorldWide Group Holding A S owned approximately 0.17% of Thermo Fisher Scientific worth $369,937,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Beacon Financial Strategies CORP acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. Olistico Wealth LLC acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. JPL Wealth Management LLC acquired a new position in Thermo Fisher Scientific in the third quarter valued at approximately $28,000. Cloud Capital Management LLC acquired a new position in Thermo Fisher Scientific in the third quarter valued at approximately $31,000. Finally, Thurston Springer Miller Herd & Titak Inc. increased its position in shares of Thermo Fisher Scientific by 195.7% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 68 shares of the medical research company's stock valued at $39,000 after buying an additional 45 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Erste Group raised its FY2027 earnings estimate for Thermo Fisher, signaling slightly better long-term profit expectations for the company. Article
• Positive Sentiment: Thermo Fisher was included in CNBC’s “Final Trades,” which can reinforce investor interest and visibility in the stock. Article
• Neutral Sentiment: Thermo Fisher continues to be viewed as a key player in life sciences tools, and a new market note questioned whether the recent pullback makes the shares more attractive from a valuation standpoint. Article
• Neutral Sentiment: Proscia’s MedTech Breakthrough Award win mentioned Thermo Fisher among industry peers, but the item was focused on Proscia rather than a direct company-specific catalyst for TMO. Article
• Negative Sentiment: Wells Fargo cut its price target on Thermo Fisher from $675 to $615, which can weigh on sentiment even though the firm kept an overweight rating. Article

Analyst Upgrades and Downgrades

A number of analysts have recently commented on TMO shares. Stifel Nicolaus cut their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating for the company in a research report on Friday, April 24th. Weiss Ratings restated a "hold (c)" rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. DZ Bank started coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a "buy" rating and a $610.00 price objective for the company. Citigroup boosted their price objective on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a "buy" rating in a research report on Friday, January 30th. Finally, UBS Group restated a "neutral" rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $619.65.

Thermo Fisher Scientific Stock Down 0.1%

Shares of TMO opened at $464.64 on Monday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The stock has a market capitalization of $172.67 billion, a price-to-earnings ratio of 25.54, a PEG ratio of 2.06 and a beta of 0.88. The stock has a 50 day moving average price of $493.53 and a 200 day moving average price of $546.70.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion during the quarter, compared to analysts' expectations of $10.86 billion. During the same period in the previous year, the business earned $5.15 earnings per share. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were given a dividend of $0.47 per share. The ex-dividend date was Friday, March 13th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.34%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares of the company's stock, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the business's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.